Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age of 18 years and older.
Chronic myeloid leukemia (CML)
Previous treatment with imatinib at a dose of \>600 mg/day AND the development of progressive disease while receiving imatinib at that dose, OR
CML with resistance to imatinib at a dose less than or equal to 600 mg/day with genetic mutation in the BCR-ABL gene that is associated with a high level of resistance to imatinib, OR
Intolerance to imatinib at any dose
Adequate organ function
Women who are able to bear children must have a negative serum or urine pregnancy test. Adequate methods of contraception must be used throughout the study to avoid pregnancy for the entire interval of at least 1 month before and 3 months after completion of the study medication.
You may not be if
Woman who are pregnant or breastfeeding
Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above
Previous diagnosis of accelerated phase or blast crisis CML.
Participants who are eligible and willing to undergo transplantation during the screening period
Uncontrolled or significant cardiovascular disease
Use of imatinib within 7 days.
Use of interferon or cytarabine within 14 days
Use of a targeted small-molecule anticancer agent within 14 days
Use of certain medication that carry a known side effect risk of Torsade de Pointes - Certain medications that irreversibly inhibit platelet function or anticoagulants
Prior therapy with dasatinib.
Clareo Health | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
